Open-label crossover trial for the efficacy and safety of switching to HIF-PH inhibitor in anemic patients with maintenance hemodialysis treated by ESA.

Open-label crossover trial for the efficacy and safety of switching to HIF-PH inhibitor in anemic patients with maintenance hemodialysis treated by ESA. - HIF-PH anemia study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042873

Enrollment

Registered

2021-01-05

Start date

2020-11-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis patient

Interventions

After treatment with Roxadustat for 12 weeks, change to the therapy of Daprodustat for 12 weeks. After treatment with Daprodustat for 12 weeks, change to the therapy of Roxadustat for 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients treated with Darbepoetin Alfa for more than 3 months before the trial. 2.Patients with stable hemoglobin level before the trial. 3.Maintenance hemodialysis and hemodiafiltration patients, three times a week.

Exclusion criteria

Exclusion criteria: 1.Patients who have difficulty in taking oral medicine. 2.Patients on concomitant peritoneal dialysis. 3.Patients judged by the investigator to be unsuitable as subjects.

Design outcomes

Primary

Measure	Time frame
Hb	—

Secondary

Measure	Time frame
Fe,ferritin,TSAT	—

Countries

Japan

Contacts

Public Contactmisaki moriishi

Nakajima tsuchiya clinic dialysis treatment center

usagi@tsuchiya-hp.jp082-542-7271

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026